PE20191482A1 - Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii - Google Patents

Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii

Info

Publication number
PE20191482A1
PE20191482A1 PE2019001866A PE2019001866A PE20191482A1 PE 20191482 A1 PE20191482 A1 PE 20191482A1 PE 2019001866 A PE2019001866 A PE 2019001866A PE 2019001866 A PE2019001866 A PE 2019001866A PE 20191482 A1 PE20191482 A1 PE 20191482A1
Authority
PE
Peru
Prior art keywords
prognosis
gastric cancer
predict
patients
benefit
Prior art date
Application number
PE2019001866A
Other languages
English (en)
Inventor
Jae Ho Cheong
Sung Hoon Noh
Yong Min Huh
Hyun Ki Kim
Original Assignee
Novomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novomics Co Ltd filed Critical Novomics Co Ltd
Publication of PE20191482A1 publication Critical patent/PE20191482A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La presente invencion se refiere a un sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio II y III, y se desarrolla un algoritmo que puede predecir el pronostico y la respuesta a quimioterapia usando resultados de analisis cuantitativo de niveles de expresion de ARNm de un grupo de genes marcadores relacionados con el pronostico o la respuesta a quimioterapia y un grupo de genes de referencia en cancer gastrico avanzado, y puede usarse como informacion complementaria para determinar un metodo para tratar un paciente con cancer gastrico
PE2019001866A 2017-03-14 2017-08-11 Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii PE20191482A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170032027 2017-03-14
PCT/KR2017/008781 WO2018169145A1 (ko) 2017-03-14 2017-08-11 진행성 위암 환자의 수술 후 예후 또는 항암제 적합성 예측 시스템

Publications (1)

Publication Number Publication Date
PE20191482A1 true PE20191482A1 (es) 2019-10-18

Family

ID=63523198

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001866A PE20191482A1 (es) 2017-03-14 2017-08-11 Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii

Country Status (17)

Country Link
US (1) US11732304B2 (es)
EP (1) EP3517624A4 (es)
JP (1) JP6864089B2 (es)
KR (2) KR101966642B1 (es)
CN (1) CN110168106B (es)
AU (1) AU2017403899B2 (es)
BR (1) BR112019019022A2 (es)
CA (1) CA3055735C (es)
CL (1) CL2019002633A1 (es)
CO (1) CO2019011359A2 (es)
IL (1) IL269256A (es)
MX (1) MX2019011017A (es)
NZ (1) NZ756580A (es)
PE (1) PE20191482A1 (es)
RU (1) RU2737449C1 (es)
UA (1) UA125590C2 (es)
WO (1) WO2018169145A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6864089B2 (ja) 2017-03-14 2021-04-21 ノヴォミクス・カンパニー・リミテッド 進行性胃癌患者の手術後の予後または抗癌剤適合性予測システム
WO2020226333A1 (ko) * 2019-05-03 2020-11-12 주식회사 디시젠 암 예후 예측방법 및 이의 조성물
KR102324294B1 (ko) * 2019-11-19 2021-11-11 서울대학교산학협력단 상피성 난소암 예후 예측 방법 및 장치
KR20220069869A (ko) 2020-11-20 2022-05-27 연세대학교 산학협력단 간암의 예후 예측을 위한 정보 제공 방법
KR102462097B1 (ko) * 2020-12-30 2022-11-02 국립암센터 삼중사중극자 다중반응 모니터링 기반 암 표적치료제 효능 예측
CN113462773A (zh) * 2021-05-19 2021-10-01 山东大学 一种预测胃癌患者生存风险、免疫治疗响应和细胞焦亡诱导剂适用性的标志物及其应用
CN114720687A (zh) * 2022-06-01 2022-07-08 浙江省肿瘤医院 Sfrp4作为胃癌预后标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1268854A4 (en) * 2000-03-27 2003-05-02 Univ Jefferson HIGH SPECIFICITY MARKER DETECTION
JPWO2005007846A1 (ja) 2003-04-25 2006-08-31 財団法人癌研究会 腫瘍細胞の抗癌剤に対する感受性を判定する方法
KR20080006315A (ko) * 2006-07-12 2008-01-16 삼성전자주식회사 전기 영동 장치 및 그의 제조 방법
ES2814027T3 (es) 2006-12-27 2021-03-25 Abion Inc Procedimiento de procesamiento y análisis de datos de expresión génica para identificar genes de referencia endógenos
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
WO2012081898A2 (ko) 2010-12-13 2012-06-21 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
KR101416147B1 (ko) * 2012-07-18 2014-07-09 국립암센터 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도
KR101504817B1 (ko) * 2013-04-05 2015-03-24 연세대학교 산학협력단 국소 진행형 위암에 대한 예후 예측 시스템
WO2015172201A1 (en) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarker of gastric cancer
US20160160290A1 (en) * 2014-11-03 2016-06-09 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
JP6864089B2 (ja) 2017-03-14 2021-04-21 ノヴォミクス・カンパニー・リミテッド 進行性胃癌患者の手術後の予後または抗癌剤適合性予測システム

Also Published As

Publication number Publication date
UA125590C2 (uk) 2022-04-27
KR20190024923A (ko) 2019-03-08
IL269256A (en) 2019-11-28
CA3055735C (en) 2021-12-14
AU2017403899B2 (en) 2021-12-09
CN110168106B (zh) 2024-02-20
CL2019002633A1 (es) 2020-04-03
NZ756580A (en) 2022-01-28
AU2017403899A1 (en) 2019-09-19
EP3517624A4 (en) 2020-04-29
MX2019011017A (es) 2020-01-20
CO2019011359A2 (es) 2019-10-31
RU2737449C1 (ru) 2020-11-30
BR112019019022A2 (pt) 2020-04-22
US20190284637A1 (en) 2019-09-19
JP6864089B2 (ja) 2021-04-21
JP2019537436A (ja) 2019-12-26
CN110168106A (zh) 2019-08-23
EP3517624A1 (en) 2019-07-31
CA3055735A1 (en) 2018-09-20
WO2018169145A1 (ko) 2018-09-20
KR102069043B1 (ko) 2020-01-22
KR20180105036A (ko) 2018-09-27
KR101966642B1 (ko) 2019-04-09
US11732304B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
PE20191482A1 (es) Sistema para predecir el pronostico y beneficio de una quimioterapia adyuvante para pacientes con cancer gastrico en estadio ii y iii
CL2020001730A1 (es) Método para el tratamiento de cáncer. (divisional solicitud 201702728)
CO7151491A2 (es) Método para la identificación del origen de un cancer de origen primario desconocido
CL2015002126A1 (es) Sistemas y métodos para soporte de decisión clínica.
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
BR112018007447A2 (pt) terapia de combinação para tratamento de malignidades
BR112018007453A2 (pt) genes modificados de ataxia de friedreich e vetores para a terapia gênica
BR112015030627A2 (pt) marcadores biológicos úteis na imunoterapia contra o câncer
BR112015002626A2 (pt) métodos para prevenção de metástases tumorais, tratamento e prognostico do câncer e identificação dos agentes que são inibidores da metástase putativa
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
CL2018000943A1 (es) Terapia de combinación para tratar tumores malignos
CL2015002807A1 (es) Terapia de combinación
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
BR112016005611A2 (pt) calreticulina mutante para o diagnóstico de malignidades mieloides
BR112018007304A2 (pt) terapia de combinação para tratamento de malignidades
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
BR112017016752A2 (pt) métodos para determinar o risco de recidiva de câncer de endométrio em um indivíduo, para predizer a recidiva em um indivíduo com câncer de endométrio, para orientar o tratamento em um indivíduo com câncer de endométrio, para detectar a instabilidade de microssatélites, e, para determinar subtipos de câncer
AU2024202148A1 (en) Determining a cancer prognosis
CL2017001487A1 (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr.
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
MA40636A (fr) Procédés pour détecter le cancer de la prostate
BR112018005331A2 (pt) inibidores de pcna